Euglycemic diabetic ketoacidosis caused by empagliflozin complicated by failure to thrive in a geriatric patient

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Jun 13, 2023
DOI: https://doi.org/10.22551/2023.39.1002.10248
Azeem Rathore Nidhi Gupta Cameron Kahn Dinesh Kadariya

Abstract

Euglycemic diabetic ketoacidosis (euDKA) is a rare but deadly complication of sodium-glucose cotransport-2 (SGLT-2) inhibitors. Primarily indicated for the treatment of Type 2 Diabetes Mellitus, the incidence of euDKA is expected to rise as SGLT-2 inhibitors become a mainstay therapy for diabetics with heart failure. Diagnosis of euDKA can be difficult given the presence of normoglycemia and is especially challenging among geriatric patients that are complicated by additional comorbidities. We present a case of an elderly male with multiple comorbidities who presented for dehydration and altered mentation from a nursing home facility. Laboratory investigations showed signs of acute renal failure, uremia, electrolyte abnormalities, and severe metabolic acidosis due to high levels of plasma beta-hydroxybutyrate. He was admitted to the medical intensive care unit (ICU) for further management. A presumptive diagnosis of euDKA was strongly suspected due to his laboratory data and medication reconciliation which revealed the recent initiation of empagliflozin. The patient was promptly started on a standardized treatment protocol for DKA with continuous infusion of regular insulin with strict glucose monitoring, along with intravenous fluids, and a small dose of sodium bicarbonate infusion as per current standard guidelines. With the rapid improvement in symptoms and metabolic derangements, the diagnosis was confirmed. Geriatric patients from nursing home facilities are a high-risk cohort who if not properly cared for by nursing staff can develop dehydration, malnutrition and worsening frailty including sarcopenia that exposes them to increased risk of medication side effects, such as euDKA. Clinicians should consider euDKA in their differential diagnosis in elderly patients with overt or relative insulinopenia who are receiving SGLT-2 inhibitors when presenting with acute changes in health and mentation.

##plugins.themes.bootstrap3.article.details##

Keywords

euglycemic diabetic ketoacidosis, SGLT-2 inhibitor, empagliflozin, geriatrics, Jardiance, failure to thrive

References
1. Simes BC, MacGregor GG. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. Diabetes Metab Syndr Obes. 2019;12:2125-2136. doi: 10.2147/DMSO.S212003. PMID: 31686884; PMCID: PMC6799898.
2. American Diabetes Association. Standards of Care in Diabetes-2023 Abridged for Primary Care Providers. Clin Diabetes. 2022;41(1):4-31. doi: 10.2337/cd23-as01. Erratum in: Clin Diabetes. 2023;41(2):328. PMID: 36714254; PMCID: PMC9845083.
3. Larkin HD. FDA Expands Empagliflozin Heart Failure Indication. JAMA. 2022;327(13):1219. doi: 10.1001/jama.2022.3970. PMID: 35380600.
4. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. PMID: 32865377.
5. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. PMID: 34449189.
6. Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes. 2021;12(5):514-523. doi: 10.4239/wjd.v12.i5.514. PMID: 33995841; PMCID: PMC8107974.
7. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev. 2017;33(8):10.1002/dmrr.2924. doi: 10.1002/dmrr.2924. PMID: 28736981; PMCID: PMC5950709.
8. Selwyn J, Pichardo-Lowden AR. Managing Hospitalized Patients Taking SGLT-2 Inhibitors: Reducing the Risk of Euglycemic Diabetic Ketoacidosis. Diabetology. 2023; 4(1):86-92. https://doi.org/10.3390/diabetology4010010
9. Pelletier R, Ng K, Alkabbani W, et al. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther Adv Drug Saf. 2021;12:2042098621989134. doi: 10.1177/2042098621989134. PMID: 33552467; PMCID: PMC7844442.
10. Lucero P, Chapela S. Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature. Case Rep Crit Care. 2018;2018:1747850. doi: 10.1155/2018/1747850. PMID: 30364093; PMCID: PMC6188774.
11. Sanusi I, Sarnowski A, Russell-Jones D, Forni LG. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition. J Crit Care. 2020;57:19-22. doi: 10.1016/j.jcrc.2019.12.007. PMID: 32007835.
12. Sehgal V, Ulmer B. Clinical Conundrums in the Management of Diabetic Ketoacidosis in the Elderly. J Transl Int Med. 2019;7(1):10-14. doi: 10.2478/jtim-2019-0003. PMID: 30997351; PMCID: PMC6463825.
13. Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10(1):548. doi: 10.1038/s41467-019-08466-w. PMID: 30710078; PMCID: PMC6358621.
14. Kayser-Jones J, Schell ES, Porter C, Barbaccia JC, Shaw H. Factors contributing to dehydration in nursing homes: inadequate staffing and lack of professional supervision. J Am Geriatr Soc. 1999;47(10):1187-94. doi: 10.1111/j.1532-5415.1999.tb05198.x. PMID: 10522951.
15. Pandya N, Hames E, Sandhu S. Challenges and Strategies for Managing Diabetes in the Elderly in Long-Term Care Settings. Diabetes Spectr. 2020;33(3):236-245. doi: 10.2337/ds20-0018. PMID: 32848345; PMCID: PMC7428662.
16. Bell CL, Lee AS, Tamura BK. Malnutrition in the nursing home. Curr Opin Clin Nutr Metab Care. 2015;18(1):17-23. doi: 10.1097/MCO.0000000000000130. PMID: 25394167.
How to Cite
Rathore, A., Gupta, N., Kahn, C., & Kadariya, D. (2023). Euglycemic diabetic ketoacidosis caused by empagliflozin complicated by failure to thrive in a geriatric patient. Archive of Clinical Cases, 10(2), Arch Clin Cases. 2023;10(2):89-92. https://doi.org/10.22551/2023.39.1002.10248
Issue
Vol. 10 No. 2 (2023)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Rathore, A., Gupta, N., Kahn, C., & Kadariya, D. (2023). Euglycemic diabetic ketoacidosis caused by empagliflozin complicated by failure to thrive in a geriatric patient. Archive of Clinical Cases, 10(2), Arch Clin Cases. 2023;10(2):89-92. https://doi.org/10.22551/2023.39.1002.10248